Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Office of the Secretary
 AGENCY: Office of the Secretary (OS), Department of Health and Human Services (HHS).
 ACTION: Notice.
 SUMMARY: Declaration pursuant to section 319F-3 of the Public Health Service Act (42 U.S.C. 247d-6d) to provide targeted liability protections for anthrax countermeasures based on a credible risk that the threat of exposure to 
                        *Bacillus anthracis*
                         and the resulting disease constitutes a public health emergency.
 DATES: This notice and the attached declaration are effective as of the date of signature of the declaration.
 FOR FURTHER INFORMATION CONTACT: RADM W.C. Vanderwagen, Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, 200 Independence Avenue, SW., Washington, DC 20201, Telephone (202) 205-2882 (this is not a toll-free number). HHS Secretary's Declaration for Utilization of Public Readiness and Emergency Preparedness Act for Anthrax Countermeasures *Whereas*
                         significant changes in the nature, regularity and degree of threats to health posed by the use of infectious agents as weapons of biological warfare have generated increased concern for the safety of the general American population particularly following the deliberate exposure of citizens in the 
                        ( print page 58240)
                        United States to 
                        *Bacillus anthracis (B. anthracis)*
                         spores in 2001 that demonstrated the ease of dissemination, infectivity, and mortality; *Whereas*
                         the Secretary of Homeland Security has determined that 
                        *B. anthracis*
                         and multi-drug-resistant 
                        *B. anthracis*
                         present a material threat against the United States population, sufficient to affect national security; *Whereas*
                         there are covered countermeasures to treat, identify, or prevent adverse health consequences or death from exposure to 
                        *B. anthracis;* *Whereas*
                         such countermeasures, including vaccines, antimicrobials/antibiotics, and antitoxins for pre-exposure and post-exposure prevention and treatment, diagnostics to identify such exposure, and additional countermeasures for treatment of adverse events arising from use of these countermeasures exist or may be the subject of research and/or development; *Whereas*
                         such countermeasures may be used and administered in accordance with Federal contracts, cooperative agreements, grants, interagency agreements, and memoranda of understanding, and may also be used and administered at the Regional, State, and local level in accordance with the public health and medical response of the Authority Having Jurisdiction; *Whereas*, the possibility of governmental program planners obtaining stockpiles from private sector entities except through voluntary means such as commercial sale, donation, or deployment would undermine national preparedness efforts and should be discouraged as provided for in section 319F-3(b)(2)(E) of the Public Health Service Act (42 U.S.C. 247d-6d(b)) (“the Act”); *Whereas*, immunity under section 319F-3(a) of the Act should be available to governmental program planners for distributions of Covered Countermeasures obtained voluntarily, such as by (1) Donation; (2) commercial sale; (3) deployment of Covered Countermeasures from Federal stockpiles; or (4) deployment of donated, purchased, or otherwise voluntarily obtained Covered Countermeasures from State, local, or private stockpiles; *Whereas*, the extent of immunity under section 319F-3(a) of the Act afforded to a governmental program planner that obtains covered countermeasures except through voluntary means is not intended to affect the extent of immunity afforded other covered persons with respect to such covered countermeasures. *Whereas*, in accordance with section 319F-3(b)(6) of the Act, I have considered the desirability of encouraging the design, development, clinical testing or investigation, manufacturing, labeling, distribution, formulation, packaging, marketing, promotion, sale, purchase, donation, dispensing, prescribing, administration, licensing, and use of such countermeasures with respect to the category of disease and population described in sections II and IV below, and have found it desirable to encourage such activities for the covered countermeasures; and *Whereas*, to encourage the design, development, clinical testing or investigation, manufacturing and product formulation, labeling, distribution, packaging, marketing, promotion, sale, purchase, donation, dispensing, prescribing, administration, licensing, and use of medical countermeasures with respect to the category of disease and population described in sections II and IV below, it is advisable, in accordance with section 319F-3(a) and (b) of the Act, to provide immunity from liability for covered persons, as that term is defined at section 319F-3(i)(2) of the Act, and to include as such covered persons such other qualified persons as I have identified in section VI of this declaration; *Therefore,*
                         pursuant to section 319F-3(b) of the Act, I have determined there is a credible risk that the threat of exposure of 
                        *B. anthracis*
                         and the resulting disease constitutes a public health emergency. I. Covered Countermeasures (As Required by Section 319F-3(b)(1) of the Act) Covered Countermeasures are defined at section 319F-3(i) of the Act. At this time, and in accordance with the provisions contained herein, I am recommending the manufacture, testing, development, distribution, dispensing; and, with respect to the category of disease and population described in sections II and IV below, the administration and usage of anthrax countermeasures as defined in section IX below. The immunity specified in section 319F-3(a) of the Act shall only be in effect with respect to: (1) Present (see Appendix I) or future Federal contracts, cooperative agreements, grants, interagency agreements, or memoranda of understanding involving countermeasures that are used and administered in accordance with this declaration, and (2) activities authorized in accordance with the public health and medical response of the Authority Having Jurisdiction to prescribe, administer, deliver, distribute or dispense the Covered Countermeasure following a declaration of an emergency, as defined in section IX below. In accordance with section 319F-3(b)(2)(E) of the Act, for governmental program planners, the immunity specified in section 319F-3(a) of the Act shall be in effect to extent they obtain Covered Countermeasures through voluntary means of distribution, such as (1) Donation; (2) commercial sale; (3) deployment of Covered Countermeasures from Federal stockpiles; or (4) deployment of donated, purchased, or otherwise voluntarily obtained Covered Countermeasures from State, local, or private stockpiles. For all other covered persons, including other program planners, the immunity specified in section 319F-3(a) of the Act shall, in accordance with section 319F-3(b)(2)(E) of the Act, be in effect pursuant to any means of distribution. This declaration shall subsequently refer to the countermeasures identified above as “Covered Countermeasures.” This declaration shall apply to all Covered Countermeasures administered or used during the effective time period of the declaration. This declaration also shall apply to all Covered Countermeasures (see Appendix I) administered or used by or on behalf of the Department of Defense. II. Category of Disease (As Required by Section 319F-3(b)(2)(A) of the Act) The category of disease, health condition, or threat to health for which I am recommending the administration or use of the Covered Countermeasures is anthrax, which may result from exposure to 
                        *B. anthracis.* III. Effective Time Period (As Required by Section 319F-3(b)(2)(B) of the Act) With respect to Covered Countermeasures administered and used in accordance with present or future Federal contracts, cooperative agreements, grants, interagency agreements, or memoranda of understanding, the effective period of time of this Declaration commences on signature of the declaration and extends through December 31, 2015. With respect to Covered Countermeasures administered and used in accordance with the public health and medical response of the Authority Having Jurisdiction, the effective period of time of this Declaration commences on the date of a declaration of an emergency and lasts through and includes the final day that the emergency declaration is in effect including any extensions thereof.
                        ( print page 58241) IV. Population (As Required by Section 319F-3(b)(2)(C) of the Act) Section 319F-3(a)(4)(A) of the Act confers immunity to manufacturers and distributors of the Covered Countermeasure, regardless of the defined population. Section 319F-3(a)(3)(C)(i) of the Act confers immunity to covered persons who may be a program planner or qualified persons with respect to the Covered Countermeasure only if a member of the population specified in the declaration as persons who use the Covered Countermeasure or to whom such a Covered Countermeasure is administered, is in or connected to the geographic location specified in this declaration, or the program planner or qualified person reasonably could have believed that these conditions are met. The populations specified in this declaration are all persons who use a Covered Countermeasure or to whom a Covered Countermeasure is administered in accordance with this declaration, including, but not limited to: Department of Defense military personnel and supporting civilian-employee and contractor personnel; any person conducting research and development of Covered Countermeasures directly by the Federal government or pursuant to a contract, grant, or cooperative agreement with the Federal government; any person who receives a Covered Countermeasure from persons authorized in accordance with the public health and medical emergency response of the Authority Having Jurisdiction to prescribe, administer, deliver, distribute, or dispense the Covered Countermeasure, and their officials, agents, employees, contractors, and volunteers following a declaration of an emergency; any person who receives a Covered Countermeasure from a person authorized to prescribe, administer or dispense the countermeasure or who is otherwise authorized under an Emergency Use Authorization; any person who receives a Covered Countermeasure as an investigational new drug in human clinical trials being conducted directly by the Federal government or pursuant to a contract, grant, or cooperative agreement with the Federal government. V. Geographic Area (As Required by Section 319F-3(b)(2)(D) of the Act) Section 319F-3(a) of the Act applies to the administration and use of a Covered Countermeasure without geographic limitation. VI. Qualified Persons (As Required by Section 319F-3(i)(8)(B) of the Act) With regard to the administration or use of a Covered Countermeasure, Section 319F-3(i)(8)(A) of the Act defines the term “qualified person” as a licensed individual who is authorized to prescribe, administer, or dispense the Covered Countermeasure under the law of the State in which such Covered Countermeasure was prescribed, administered or dispensed. Additional persons who are qualified persons pursuant to section 319F-3(i)(8)(B) are the following: (1) Any person who is authorized to prescribe, administer, deliver, distribute or dispense Covered Countermeasures to Department of Defense military personnel and supporting civilian-employee and contractor personnel, (2) Any person authorized in accordance with the public health and medical emergency response of the Authority Having Jurisdiction to prescribe, administer, deliver, distribute or dispense Covered Countermeasures, and their officials, agents, employees, contractors and volunteers, following a declaration of an emergency, and (3) Any person authorized to prescribe, administer, or dispense Covered Countermeasures or who is otherwise authorized under an Emergency Use Authorization, including, but not limited to Department of Defense military personnel and supporting civilian employee and contractor personnel. VII. Additional Time Periods of Coverage After Expiration of Declaration (As Required by Section 319F-3(b)(3)(B) of the Act) I have determined that, upon expiration of the time period specified in Section III above, an additional twelve (12) months is a reasonable period to allow for manufacturers and other covered persons to take such other actions as are appropriate to limit the administration or use of the Covered Countermeasure, and the liability protection of section 319F-3(a) of the Act shall extend for that period. Further, as to doses shipped by the CDC to the DoD pursuant to the DoD/CDC Interagency Agreement (IAA) dated March 10, 2008, an additional period of time of liability protection shall extend for as long as the SNS or its successor exists and the IAA remains in effect, plus, if the additional twelve (12) months following the time period in Section III above has expired, an additional twelve (12) months upon expiration of the IAA. VIII. Amendments This declaration has not previously been amended. Any future amendment to this declaration will be published in the 
                        **Federal Register**
                        , pursuant to section 319F-3(b)(4) of the Act. IX. Definitions For the purpose of this declaration, including any claim for loss brought in accordance with section 319F-3 of the PHS Act against any covered persons defined in the Act or this declaration, the following definitions will be used: *Administration of a Covered Countermeasure:*
                         As used in Section 319F-3(a)(2)(B) of the Act includes, but is not limited to, public and private delivery, distribution, and dispensing activities relating to physical administration of the Covered Countermeasures to patients/recipients, management and operation of delivery systems, and management and operation of distribution and dispensing locations. *Anthrax Countermeasure:*
                         Any vaccine; antimicrobial/antibiotic, other drug or antitoxin; or diagnostic or device to identify, prevent or treat anthrax or adverse events from such countermeasures (1) Licensed under section 351 of the Public Health Service Act; (2) approved under section 505 or section 515 of the Federal Food, Drug, and Cosmetic Act (FDCA); (3) cleared under section 510(k) of the FDCA; (4) authorized for emergency use under section 564 of the FDCA ; (5) used under section 505(i) of the FDCA or section 351(a)(3) of the PHS Act, and 21 CFR Part 312; or (6) used under section 520(g) of the FDCA and 21 CFR part 812. *Authority Having Jurisdiction:*
                         The public agency or its delegate that has legal responsibility and authority for responding to an incident, based on political or geographical (e.g., city, county, tribal, State, or Federal boundary lines) or functional (e.g., law enforcement, public health) range or sphere of authority. *Covered persons:*
                         As defined at section 319F-3(i)(2) of the Act include the United States, manufacturers, distributors, program planners, and qualified persons. The terms “manufacturer,” “distributor,” “program planner,” and “qualified person” are further defined at sections 319F-3(i)(3), (4), (6), and (8) of the Act. *Declaration of an emergency:*
                         A declaration by any authorized local, regional, State, or federal official of an emergency specific to events that indicate an immediate need to administer and use anthrax countermeasures, with the exception of 
                        ( print page 58242)
                        a federal declaration in support of an emergency use authorization under section 564 of the FDCA unless such declaration specifies otherwise. This first day of October, 2008. Michael O. Leavitt, Secretary of Health and Human Services.
 Appendix I—List of U.S. Government Contracts
Contract
Manufacturer
Covered countermeasure
PL 85-804 
                                 coverage*HHSO100200500007C
Cangene
Anthrax immune globulin—AIG
No.HHSO100200500006C
HGS
Anthrax monoclonal antibody-ABThrax
No.HHSO100200600019C
Emergent Biodefense Operations
BioThrax (Anthrax Vaccine Adsorbed, AVA)
Yes.HHSO100200700037C
Emergent Biodefense Operations
BioThrax (Anthrax Vaccine Adsorbed, AVA)
No.W9113M-04-D-0002
BioPort (Emergent Biosolutions)
BioThrax (Anthrax Vaccine Adsorbed, AVA)
Yes.DAMD 17-97-D-00003
BioPort (Emergent Biosolutions)
BioThrax (Anthrax Vaccine Adsorbed, AVA) Shipping
Yes.HHSN 272200700035C
Elusys
Anthrax monoclonal antibody—ETI-204
No.HHSN 272200700033C
Pharmathene
Anthrax monoclonal antibody—Valortim
No.HHSN 272200700034C
Emergent BioSolutions
Anthrax immune globulin—AIG
No.NO1-A1-30052
Avecia (Pharmathene)
Recombinant protective antigen (rPA) anthrax vaccine
No.V797P-5777x
Shering Corp.
Cipro 250mg/5ml; 100ml suspension
No.V797P-5977x
Cobalt Pharmaceuticals
Cipro 500mg tablets
No.V797P-5941x
Blu Pharmaceuticals
Doxycycline 100mg tablets
No.V797P-5883x
Pfizer, Inc
Doxycycline 25mg/5ml suspension 60ml
No.V797P-5669x
Abraxis Bioscience, Inc
Doxycycline 100mg vial IV
No.V797-DSNS-8002
Sandoz, Inc
Amoxicillin 500mg capsules
No.V797-DSNS-8002
Sandoz, Inc
Amoxicillin 400mg/5ml; 100ml suspension
No.V797BPA0015
Bedford Labs
Rifampin 600mg vial IV
No.V797P-5396x
Hospira
Clindamycin 150mg/ml 6ml vial IV
No.V797P-5669x
Abraxis Bioscience, Inc
Vancomycin 1 g vial IV
No.V797P-1020x
McKesson
Penicillin GK 20 million unit vial IV
No.V797P-5387x
Johnson and Johnson Healthcare
Levofloxacin 5mg/ml 150ml bag IV
No.* Status of indemnification coverage under P.L. 85-804 (An Act to authorize the making, amendment and modification of contracts to facilitate the national defense.)


[FR Doc. E8-23547 Filed 10-1-08; 4:15 pm] BILLING CODE 4150-37-P